Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Farmers Insurance
Johnson and Johnson
Cantor Fitzgerald
Queensland Health

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,703,035

« Back to Dashboard

Summary for Patent: 4,703,035

Title: Human pancreatic GRF amidated fragments
Abstract:Surprisingly active fragments of human pancreatic GRF have been synthesized which exhibit good biological activity. These synthetic peptides are extremely potent in stimulating the release of pituitary GH in humans and in nonhuman animals and have the general formula: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser- Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Y wherein Y is NH.sub.2, Gln-NH.sub.2, Gln-Gln-NH.sub.2 or Gln-Gln-Gly-NH.sub.2. Two such fragments have been tested, namely the 29 and the 32 N-terminal residue sequences that are amidated at the C-terminus. These peptides, as well as nontoxic salts thereof, may be administered therapeutically to animals, including humans.
Inventor(s): Rivier; Jean E. F. (La Jolla, CA), Spiess; Joachim (Encinitas, CA), Vale, Jr.; Wylie W. (La Jolla, CA)
Assignee: The Salk Institute for Biological Studies (San Diego, CA)
Application Number:06/782,912
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

International Patent Family for Patent: 4,703,035

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina241452► Subscribe
Austria24919► Subscribe
Austria25851► Subscribe
Austria36862► Subscribe
Austria73823► Subscribe
Australia2126983► Subscribe
Australia2307584► Subscribe
Australia3259484► Subscribe
Australia4248885► Subscribe
Australia557046► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
US Department of Justice
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus